Osimertinib
Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) primarily used in the treatment of advanced non-small cell lung cancer (NSCLC) harboring specific EGFR mutations, particularly the exon 19 deletions and the L858R point mutation.
Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) primarily used in the treatment of advanced non-small cell lung cancer (NSCLC) harboring specific EGFR mutations, particularly the exon 19 deletions and the L858R point mutation. It functions by irreversibly binding to the EGFR tyrosine kinase domain, inhibiting downstream signaling pathways that promote tumor growth and survival. This selective inhibition leads to reduced proliferation of cancer cells and has been associated with improved clinical outcomes in patients with EGFR-mutated NSCLC.
The drug's significance lies in its ability to overcome resistance mechanisms that limit the efficacy of earlier-generation EGFR TKIs, such as gefitinib and erlotinib. Osimertinib has been shown to provide substantial benefits in terms of progression-free survival (PFS) and overall survival in various clinical settings, making it a cornerstone in the management of EGFR-mutated lung cancer.
Where the papers sit
16 papers from the last 6 months study osimertinib directly · updated from PubMed 15 Nov 2026
Study type 4 clinical trials · 3 observational · 4 human data · 4 preclinical · 1 unclassified
Themes 3 themes · 2 new directions
-
EGFR-Mutant Lung Cancer
Front-line osimertinib is being refined by EGFR subtype, TP53 co-mutation, EGFR amplification and treatment setting in advanced NSCLC. Adding chemotherapy is being tested for TP53-mutant disease, while selumetinib targets BRAF-altered progression. Resistance work points to Wnt-driven stemness, drug-tolerant persisters and occasional small-cell transformation. Brain and suprasellar metastases remain important endpoints alongside progression-free survival and safety. Real-world pharmacovigilance and definitive-CRT studies are extending evidence beyond metastatic trials.
13 papers · 81.2%
-
Savolitinib Combination Pharmacology
MET-directed therapy with savolitinib is being characterized through exposure-response modeling, alone and with osimertinib. Pharmacokinetic covariates and drug exposure are being linked to response in locally advanced or metastatic disease. MET amplification or expression, assessed by FISH and immunohistochemistry, anchors biomarker selection. The work remains focused on quantitative dose optimization rather than establishing a new treatment standard.
1 papers · 6.2%
-
Others — Dual-Action Therapeutic Design
One line targets DDRGK1 and UFMylation alongside macrophage and PD-1 biology in glioblastoma, seeking durable regression. Another uses bioorthogonal retro-Cope/Cope elimination for sequential prodrug activation. These mechanisms and disease settings do not converge on a shared biological question. Their commonality is limited to dual therapeutic activation, so no unified research direction is evident.
2 papers · 12.5%
Osimertinib is repurposed as a covalent UFMylation inhibitor in glioblastoma
The glioblastoma study treats osimertinib, ordinarily presented as an EGFR T790M-selective inhibitor for EGFR-mutant lung cancer, as a covalent inhibitor of the UFMylation E3-ligase component DDRGK1 instead. By disrupting the DDRGK1–UFL1 interaction, osimertinib suppresses UFMylation, induces ER stress, affects macrophage polarization, and produces tumor regression in glioblastoma models, establishing a non-EGFR therapeutic role for the drug 42472853Jul.
Osimertinib is incorporated as a conditionally activated payload in a dual prodrug system
The bioorthogonal prodrug study uses osimertinib not as a directly administered EGFR-targeted therapy but as one covalent inhibitor payload coactivated with doxorubicin or CA4 through a tandem retro-Cope/Cope-elimination strategy. This assigns osimertinib a new role as a component of a dual-activation chemical-delivery platform for combination therapy 42138023May.
Papers
The 16 papers from the last 6 months that study osimertinib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
EGFR-Mutant Lung Cancer (13)
- PMID 42142703
- Long-term Disease Control After Probable Endobronchial Small-cell Transformation During Osimertinib Therapy for EGFR-mutant Lung Adenocarcinoma. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957218
- Transcriptomic and network analyses identify epigenetic regulators of drug-tolerant persister (DTP) subsets in EGFR-mutant HCC827 non-small cell lung cancer. Genes & genomics · 15 Sept 2026 PMID 42742903
- Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) · 3 Sept 2026 PMID 42691830
- The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC). Lung cancer (Amsterdam, Netherlands) · 27 Aug 2026 PMID 42660014
- Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial. JAMA · 10 Aug 2026 PMID 42574006
- Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Receiving First-line Osimertinib. Clinical cancer research : an official journal of the American Association for Cancer Research · 14 Jul 2026 PMID 42446521
- Rescue of Suprasellar Metastasis of EGFR-mutant NSCLC by Daily Osimertinib Re-escalation With Filgrastim Support. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379747
- Selectively targeting inosine monophosphate dehydrogenase-2 impairs brain metastatic potential while preserving immune cell function. Proceedings of the National Academy of Sciences of the United States of America · 17 Jun 2026 PMID 42308042
- Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study. Lung cancer (Amsterdam, Netherlands) · 15 Jun 2026 PMID 42296617
- Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD. European journal of cancer (Oxford, England : 1990) · 27 May 2026 PMID 42202477
- A real-world pharmacovigilance study of four anti-non-small cell lung cancer drugs using the WHO-VigiAccess database. Medicine · 23 May 2026 PMID 42175505
- Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH). Cancer biology & medicine · 22 May 2026 PMID 42170792
Savolitinib Combination Pharmacology (1)
- Population Pharmacokinetics and Exposure-Response Analyses of Savolitinib Alone or in Combination With Osimertinib in Patients With Locally Advanced or Metastatic Solid Tumors. Clinical and translational science · 25 Aug 2026 PMID 42638263
Others — Dual-Action Therapeutic Design (2)
- PMID 42138023
- Dual-targeting pharmacological UFMylation inhibition reprograms tumor and immune microenvironments to achieve long-term glioblastoma regression. Signal transduction and targeted therapy · 19 Jul 2026 PMID 42472853
By study type
Clinical trials (4)
- Population Pharmacokinetics and Exposure-Response Analyses of Savolitinib Alone or in Combination With Osimertinib in Patients With Locally Advanced or Metastatic Solid Tumors. Clinical and translational science · 25 Aug 2026 PMID 42638263
- Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial. JAMA · 10 Aug 2026 PMID 42574006
- Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study. Lung cancer (Amsterdam, Netherlands) · 15 Jun 2026 PMID 42296617
- Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD. European journal of cancer (Oxford, England : 1990) · 27 May 2026 PMID 42202477
Observational studies and case reports (3)
- Long-term Disease Control After Probable Endobronchial Small-cell Transformation During Osimertinib Therapy for EGFR-mutant Lung Adenocarcinoma. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957218
- Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) · 3 Sept 2026 PMID 42691830
- Rescue of Suprasellar Metastasis of EGFR-mutant NSCLC by Daily Osimertinib Re-escalation With Filgrastim Support. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379747
Human data, design not indexed (4)
- Osimertinib, platinum, and etoposide for patients with metastatic EGFR/TP53/RB1-mutant lung cancers at risk for histological transformation. Science translational medicine · 11 Nov 2026 PMID 43013682
- The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC). Lung cancer (Amsterdam, Netherlands) · 27 Aug 2026 PMID 42660014
- Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Receiving First-line Osimertinib. Clinical cancer research : an official journal of the American Association for Cancer Research · 14 Jul 2026 PMID 42446521
- A real-world pharmacovigilance study of four anti-non-small cell lung cancer drugs using the WHO-VigiAccess database. Medicine · 23 May 2026 PMID 42175505
Preclinical: animal, cell and lab studies (4)
- Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma. Journal of biomedical science · 12 Nov 2026 PMID 43021317
- Transcriptomic and network analyses identify epigenetic regulators of drug-tolerant persister (DTP) subsets in EGFR-mutant HCC827 non-small cell lung cancer. Genes & genomics · 15 Sept 2026 PMID 42742903
- Dual-targeting pharmacological UFMylation inhibition reprograms tumor and immune microenvironments to achieve long-term glioblastoma regression. Signal transduction and targeted therapy · 19 Jul 2026 PMID 42472853
- Selectively targeting inosine monophosphate dehydrogenase-2 impairs brain metastatic potential while preserving immune cell function. Proceedings of the National Academy of Sciences of the United States of America · 17 Jun 2026 PMID 42308042
Unclassified: not yet indexed with MeSH (1)
- Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH). Cancer biology & medicine · 22 May 2026 PMID 42170792
Written from 16 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.